Abstract 427P
Background
Tumor tissue comprehensive genomic profiling (CGP) identifies molecular targets for precision oncology but with turnaround time (TAT) around one month. We conducted tumor tissue CGP for advanced stage cancer pts from AME using a new and potentially faster tissue-based NGS platform.
Methods
Using DNA-based hybrid capture technology, Guardant360 TissueNext™ reports point mutations and insertions/deletions in 84 genes, fusions for 13 activating partners, amplification (amp) of 20 genes, tumor mutation burden (TMB) score, and microsatellite instability (MSI) status.
Results
Tumor tissue from 412 pts was tested, with success rate 87.3%. Median pt age was 61 years; 54% were male. Median TAT was 15 days (range, 6-127). Mean alteration count/sample was 3.1 (range, 1-29) and mean variant allelic frequency was 19.4% (range, 1.7-88.3). The most profiled cancers included lung (49.4%), colon or rectum (CRC; 9.0%) and breast (6.0%). TP53 (64.6%), EGFR (26.9%) and KRAS (19.0%) were the most mutated genes. EGFR (18.4%), FGFR1 (6.6%) and CCNE1 (6.6%) were the most frequently amplified genes. Fusions were identified in 30 (8.2%) pts and included ALK (2.7%), ROS1 (1.4%) and RET (1.4%). MSI-high was reported for 1.1% and TMB ≥10 mutations/Mb was found in 11.7%. For non-small cell lung cancer (n=176), alterations in genes recommended for testing by the National Comprehensive Cancer Network were mutations in EGFR (53.4%), KRAS (11.5%; 4.3% G12C), ERBB2 (3.7%) and BRAF V600E (1.4%); fusions of ALK (5.5%), ROS1 (2%), RET (2%) and NTRK1/3 (1.7% combined); MET exon14 skipping (1.7%) and MET amp (5.6%). MSI-high and TMB≥10 mutations/Mb were found in 0.7% and 12%, respectively. For CRC (n=33), informative alterations included KRAS mutations (45.4%), BRAF V600E (3%), and ERBB2 amp (6%); 1 patient each had RET and NTRK1 fusions. In breast cancer (n=22), relevant alterations included ERBB2 amp (22%) and mutations in PIK3CA (43%), ESR1 (4.8%), ERBB2 (4.8%) and BRCA1/2 (4.8%).
Conclusions
This analysis of the first tumor samples tested by a new CGP panel in AME demonstrated detection of actionable alterations at the expected frequency with only 15 days median TAT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
N. Sandhir, S. Olsen: Financial Interests, Personal, Full or part-time Employment: Guardant Health. All other authors have declared no conflicts of interest.
Resources from the same session
238P - Enfortumab-vedotin for metastatic urothelial carcinoma refractory to platinum-based chemotherapy and immune checkpoint inhibitors: A single institution experience
Presenter: Yuki Endo
Session: Poster Display
Resources:
Abstract
239P - Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy
Presenter: Ryuichi Mizuno
Session: Poster Display
Resources:
Abstract
240P - Efficacy and safety of first-line combination therapy with ipilimumab + nivolumab for metastatic renal cell carcinoma in a single institution in Japan
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
241P - First-line cabozantinib in metastatic renal cell carcinoma (mRCC): A real-world exploratory study from eastern India
Presenter: Tamojit Chaudhuri
Session: Poster Display
Resources:
Abstract
244P - Clinicopathologic feature and treatment outcome of metastatic non clear cell kidney cancer: A single centre experience from India
Presenter: Somnath Roy
Session: Poster Display
Resources:
Abstract
245P - The role of TGF-β in the formation of the protumor phenotype of circulating neutrophils at different stages of renal cancer
Presenter: Ilseya Myagdieva
Session: Poster Display
Resources:
Abstract
246P - Impact of renal impairment on first-line treatment in metastatic urothelial cancer
Presenter: Stephanie Wakeling
Session: Poster Display
Resources:
Abstract
247P - Adjuvant chemoradiotherapy in the management of bladder adenocarcinoma compared to multiple treatment modalities
Presenter: Othman Mohammed
Session: Poster Display
Resources:
Abstract
248P - Screening zinc homeostasis-related genes identifies metallothionein 1H (MT1H) as a potential prognostic biomarker in clear cell renal cell carcinoma (ccRCC)
Presenter: Eyad Al Masoud
Session: Poster Display
Resources:
Abstract
249P - The prognostic utility of Progestogen associated Endometrial protein (PAEP) gene expression in clear cell renal cell carcinoma (ccRCC)
Presenter: Leen Lataifeh
Session: Poster Display
Resources:
Abstract